ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX technology to boost the antibody’s ADCC anti-tumor activity.
 
The GlymaxX technology for production of afucosylated proteins is universally applicable, simple and potent. The advantage of the GlymaxX technology is that a single GlymaxX modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The technology can be integrated in newly developed or already existing cell lines of different origins.
 
Berlin-based ProBioGen specializes in developing and manufacturing complex therapeutic glycoproteins. Combining both state-of-the-art development platforms, based on ProBioGen’s CHO.RiGHT expression and manufacturing platform, together with intelligent product-specific technologies, yields biologics with optimized properties.